Latest Articles
How invisible symptoms and provider bias delay endometriosis diagnosis - Contemporary OB/GYN
How invisible symptoms and provider bias delay endometriosis diagnosis Contemporary OB/GYN
Published: Dec. 2, 2025, 2:02 p.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire
Published: Dec. 2, 2025, 1:05 p.m.
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia - Stock Titan
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia Stock Titan
Published: Dec. 2, 2025, 1:05 p.m.
Amy Schumer says she lost 50lbs to 'survive' potentially fatal disease - LADbible
Amy Schumer says she lost 50lbs to 'survive' potentially fatal disease LADbible
Published: Dec. 2, 2025, 12:46 p.m.
Ziwig Publishes Validation Study for Saliva-Based Endometriosis Test - Femtech Insider
Ziwig Publishes Validation Study for Saliva-Based Endometriosis Test Femtech Insider
Published: Dec. 2, 2025, 11:38 a.m.
Fun-filled fashion show helped raise hundreds of pounds for West Lothian charity - Daily Record
Fun-filled fashion show helped raise hundreds of pounds for West Lothian charity Daily Record
Published: Dec. 2, 2025, 11:22 a.m.
As women with ‘invisible illnesses’ struggle to be believed, a report on chronic pain could help - CBC
As women with ‘invisible illnesses’ struggle to be believed, a report on chronic pain could help CBC
Published: Dec. 2, 2025, 11 a.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer
Published: Dec. 2, 2025, 7:30 a.m.
Link copied to clipboard!